{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T09:48:43Z","timestamp":1779356923199,"version":"3.51.4"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.intimp.2014.05.031","type":"journal-article","created":{"date-parts":[[2014,6,9]],"date-time":"2014-06-09T21:30:47Z","timestamp":1402349447000},"page":"481-486","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Evaluation of circulating levels of inflammatory and bone formation markers in axial spondyloarthritis"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6377-6568","authenticated-orcid":false,"given":"Kenia Rodrigues","family":"de Andrade","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1406-8244","authenticated-orcid":false,"given":"Gl\u00e1ucio Ricardo Werner","family":"de Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6110-7539","authenticated-orcid":false,"given":"Geison","family":"Vicente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia Salvan","family":"da Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Nader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivanio Alves","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5101-1442","authenticated-orcid":false,"given":"T\u00e2nia Silvia","family":"Fr\u00f6de","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2014.05.031_bb0005","series-title":"Rheumatology","first-page":"1109","author":"Hockberg","year":"2007"},{"key":"10.1016\/j.intimp.2014.05.031_bb0010","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.rdc.2012.08.003","article-title":"Pathophysiology of new bone formation and ankylosis in spondyloarthritis","volume":"38","author":"Lories","year":"2012","journal-title":"Rheum Dis Clin North Am"},{"issue":"3","key":"10.1016\/j.intimp.2014.05.031_bb0015","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.berh.2006.03.001","article-title":"Pathogenesis of ankylosing spondylitis: current concepts","volume":"20","author":"Smith","year":"2009","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.intimp.2014.05.031_bb0020","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/rheumatology\/36.7.766","article-title":"The outcome of ankylosing spondylitis: a study of 100 patients","volume":"36","author":"Jt","year":"1997","journal-title":"Br J Rheumatol"},{"issue":"3","key":"10.1016\/j.intimp.2014.05.031_bb0025","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/art.23260","article-title":"Critical appraisal of assessment of structural damage in ankylosing spondylitis\u2014implications for treatment outcomes","volume":"58","author":"Sieper","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.intimp.2014.05.031_bb0030","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/art.1780380407","article-title":"Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis","volume":"38","author":"Braun","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.intimp.2014.05.031_bb0035","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/ard.2005.037465","article-title":"Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases","volume":"65","author":"Francois","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.intimp.2014.05.031_bb0040","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","article-title":"Enbrel ankylosing spondylitis study group: recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial","volume":"48","author":"Davis","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.intimp.2014.05.031_bb0045","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1136\/ard.54.7.556","article-title":"Evidence of impaired cartilage\/bone turnover in patients with active ankylosing spondylitis","volume":"54","author":"Marhoffer","year":"1995","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.intimp.2014.05.031_bb0050","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/1478-6354-13-S1-S4","article-title":"Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future","volume":"13","author":"Schett","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.intimp.2014.05.031_bb0055","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/MAJ.0b013e31820f8b29","article-title":"Structural bone changes in spondyloarthritis: mechanisms, clinical impact and therapeutic considerations","volume":"341","author":"Schett","year":"2011","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.intimp.2014.05.031_bb0060","doi-asserted-by":"crossref","first-page":"R125","DOI":"10.1186\/ar2537","article-title":"Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spodyloarthritis with and without tumor necrosis factor-alpha blocker treatment","volume":"10","author":"Appel","year":"2008","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.intimp.2014.05.031_bb0065","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1136\/ard.61.12.1047","article-title":"Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis","volume":"61","author":"Crotti","year":"2002","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.intimp.2014.05.031_bb0070","first-page":"1430","article-title":"Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation","volume":"29","author":"Grisar","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.intimp.2014.05.031_bb0075","first-page":"2236","article-title":"Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis","volume":"31","author":"Franck","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.intimp.2014.05.031_bb0080","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nm1538","article-title":"Dickkopf-1 is a master regulator of joint remodeling","volume":"13","author":"Diarra","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.intimp.2014.05.031_bb0085","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/rheumatology\/keh317","article-title":"Protein oxidation status in patients with ankylosing spondylitis","volume":"43","author":"Yazici","year":"2004","journal-title":"Rheumatology"},{"key":"10.1016\/j.intimp.2014.05.031_bb0090","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s00296-007-0352-3","article-title":"Serum oxidative\u2013antioxidative status in patients with ankylosing spondylitis","volume":"27","author":"Karakoc","year":"2007","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.intimp.2014.05.031_bb0095","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1093\/rheumatology\/kes193","article-title":"Myeloperoxidase and oxidative stress in rheumatoid arthritis","volume":"51","author":"Stamp","year":"2012","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.intimp.2014.05.031_bb0100","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1007\/s00296-011-1912-0","article-title":"Serum adenosine deaminase may predict disease activity in rheumatoid arthritis","volume":"32","author":"Zamani","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.intimp.2014.05.031_bb0110","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria","volume":"27","author":"Van der Linden","year":"1984","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.intimp.2014.05.031_bb0115","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of Spondyloarthritis International Society (ASAS) classification criteria for axial spondyloarthritis: validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.intimp.2014.05.031_bb0120","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0003-2697(82)90118-X","article-title":"Analysis of nitrate, nitrite and [15N] nitrate in biological fluids","volume":"126","author":"Green","year":"1982","journal-title":"Anal Biochem"},{"key":"10.1016\/j.intimp.2014.05.031_bb0125","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/BF00920477","article-title":"Comparative evaluation of arachidonic acid (aa)- and tetradecanoylphorbol acetate (TPA)-induced dermal inflammation","volume":"17","author":"Rao","year":"1993","journal-title":"Inflammation"},{"key":"10.1016\/j.intimp.2014.05.031_bb0130","series-title":"Adenosine deaminase: colourimetric method. Methods of enzymatic analysis","first-page":"315","author":"Giusti","year":"1984"},{"issue":"9","key":"10.1016\/j.intimp.2014.05.031_bb0135","first-page":"1694","article-title":"Defining spinal mobility in ankylosing spondylitis (the bath as metrology index)","volume":"21","author":"Jenkinson","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.intimp.2014.05.031_bb0140","first-page":"2281","article-title":"A new approach to defining functional ability in ankylosing spondylitis: the development of the bath ankylosing spondylitis functional index","volume":"21","author":"Calin","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.intimp.2014.05.031_bb0145","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.intimp.2014.05.031_bb0150","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10067-006-0283-5","article-title":"Comparison of serum IL-1\u03b2, sIL-2R, IL-6, and TNF-\u03b1 levels with disease activity parameters in ankylosing spondylitis","volume":"26","author":"Bal","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.intimp.2014.05.031_bb0155","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2014.05.031_bb0160","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"The ATLAS study group efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"Van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.intimp.2014.05.031_bb0165","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23471","article-title":"Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept","volume":"58","author":"Van der Heijde","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.intimp.2014.05.031_bb0170","article-title":"Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8years in patients with ankylosing spondylitis","author":"Baraliakos","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.intimp.2014.05.031_bb0175","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2012-eular.2243","article-title":"The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4years of the GO-RAISE trial","author":"Braun","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.intimp.2014.05.031_bb0180","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/art.21054","article-title":"Non steroidal anti-inflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial","volume":"52","author":"Wanders","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.intimp.2014.05.031_bb0185","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0889-857X(05)70067-3","article-title":"The role of nitric oxide in articular cartilage damage","volume":"25","author":"Lotz","year":"1999","journal-title":"Rheum Dis Clin North Am"},{"issue":"5","key":"10.1016\/j.intimp.2014.05.031_bb0190","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1136\/ard.59.5.338","article-title":"The oxidative metabolism of circulating phagocytes in ankylosing spondylitis: determination by whole blood chemiluminescence","volume":"59","author":"Ho","year":"2000","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.intimp.2014.05.031_bb0195","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/rheumatology\/41.8.883","article-title":"Tumour necrosis factor alpha stimulates nitric oxide production more potently than interleukin-1beta in porcine articular chondrocytes","volume":"41","author":"Goodstone","year":"2002","journal-title":"Rheumatol"},{"issue":"11","key":"10.1016\/j.intimp.2014.05.031_bb0200","first-page":"2428","article-title":"Lymphocytic infiltration and expression of inducible nitric oxide synthase in human duodenal and colonic mucosa is a characteristic of ankylosing spondylitis","volume":"30","author":"Lamarque","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.intimp.2014.05.031_bb0205","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1007\/s00296-011-1981-0","article-title":"Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy","volume":"32","author":"Kwon","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.intimp.2014.05.031_bb0210","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/1471-2474-13-191","article-title":"Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis","volume":"13","author":"Taylan","year":"2012","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.intimp.2014.05.031_bb0215","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/art.27231","article-title":"Evidence that DKK-1 is dysfunctional in ankylosing spondylitis","volume":"62","author":"Daoussis","year":"2010","journal-title":"Arthritis Rheum"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576914002112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576914002112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T19:56:12Z","timestamp":1597953372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576914002112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S1567576914002112"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2014.05.031","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of circulating levels of inflammatory and bone formation markers in axial spondyloarthritis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2014.05.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}